Search
Research
Cystic FibrosisCystic fibrosis (CF) is the most common chronic, life-shortening genetic condition affecting young Australians. There is no cure but researchers are working to prevent the onset of lung disease.
News & Events
MRCF launches Perth-based biotech developing new treatment for Cystic FibrosisA The Kids Research Institute Australia spin-off company has received $20 million from the Medical Research Commercialisation Fund to develop a promising new therapy for the treatment of Cystic Fibrosis.
News & Events
My child is wheezing – what should I do?Almost 50 per cent of preschool children will experience at least one episode of wheeze, a whistling sound produced by the airways during breathing.
The Wal-yan Respiratory Research Centre is made up of multi-disciplinary teams that are committed to improving the lives of children and their families living with respiratory disease.
Research
InfluenzaInfluenza (commonly known as the flu) is caused by a highly contagious virus spread mainly through coughing and sneezing. An annual flu vaccination is the most effective way to prevent flu outbreaks.
Research
The STAMP RSV ProgramSTAMP RSV is a multifaceted program of work with the single focus to prepare the community for the uptake of new and emerging RSV immunisation strategies by providing the evidence to inform public health policy.
News & Events
New partnership with Down Syndrome WAResearchers from the Wesfarmers Centre of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, are partnering with Down Syndrome WA to learn more about how respiratory syncytial virus, or RSV, affects children with increased medical vulnerability.
News & Events
Childhood influenza vaccination rates improves with better accessMore children across Australia are being vaccinated against the flu since funding was expanded and access widened under the National Immunisation Program
Research
Clinical Management of Staphylococcus aureus Bacteremia in Neonates, Children, and AdolescentsStaphylococcus aureus is a common cause of community and health care-associated bacteremia, with authors of recent studies estimating the incidence of S aureus bacteremia (SAB) in high-income countries between 8 and 26 per 100 000 children per year. Despite this, <300 children worldwide have ever been randomly assigned into clinical trials to assess the efficacy of treatment of SAB.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.